Investigational drug · Phase 2
RBD1016
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis D, Chronic Hepatitis b.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
4
Any phase or sponsor naming "RBD1016"
First trial start
2023
Oct 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RBD1016", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis D
- Chronic Hepatitis b
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "RBD1016" as an intervention, largest first.
Suzhou Ribo Life Science Co. Ltd.Industry
NCT05961098 · 48 participants · Start Oct 11, 2023 · Primary completion Apr 29, 2025
Drug: RBD1016 · For: Chronic Hepatitis b
Sites: Hong Kong, China; Stockholm, Sweden; Uppsala, Sweden · 4 sites in all
Suzhou Ribo Life Science Co. Ltd.Industry
NCT05017116 · 40 participants · Start Aug 9, 2021 · Primary completion Oct 25, 2023
Drug: RBD1016; Placebo and 1 more · For: Chronic Hepatitis B
Sites: Hong Kong, China
Suzhou Ribo Life Science Co. Ltd.Industry
NCT04685564 · 32 participants · Start Feb 5, 2021 · Primary completion Sep 8, 2021
Drug: RBD1016; Placebo · For: Healthy Volunteers
Sites: Randwick, Australia
- Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis DActive, not recruiting
Ribocure Pharmaceuticals ABIndustry
NCT06649266 · 14 participants · Start Aug 21, 2024 · Primary completion Sep 24, 2026
Drug: RBD1016; Placebo · For: Chronic Hepatitis D
Sites: Stockholm, Sweden · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A potent GalNAc-siRNA drug, RBD1016, leads to sustained HBsAg reduction and seroconversion in mouse models of HBV infection.
Zheng S, Cao H, Zhang M, et al. · Mol Ther Nucleic Acids 2025
- Analysis of the pharmacokinetics and efficacy of RBD1016 - A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK/PD model.
Li Q, Geng T, Li H, et al. · Heliyon 2024
- Metabolite identification and quantitation of RBD1016 siRNA: a direct comparison of hybridization-based LC-FD and LC-HRAM assays.
Ji Y, Guo Z, Yan M, et al. · Bioanalysis 2024
Also in development for Chronic Hepatitis D
- BrelovitugBJT-778, BTGPhase 34 trials
Mirum Pharmaceuticals, Inc. · Chronic Hepatitis D Infection, Chronic Hepatitis D
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.